September 19, 2017

Nokia Oyj (ADR) (NYSE:NOK) plan to cut almost 600 jobs in France

French junior economy minister Benjamin Griveaux said on Tuesday, Nokia Oyj (ADR) (NYSE:NOK)’s  plan to cut almost 600 jobs in France is suspended until Oct. 2,  after meeting the head of the Finnish telecom equipment maker’s French unit.

Griveaux will meet with unions and company management on Oct. 2 to check whether Nokia is following on an earlier pledge to increase research and development (R&D) jobs in France.

“At this stage, the jobs cut plan is suspended … at least until this meeting that I will chair on Oct. 2 at the finance ministry,” Griveaux told reporters.

Nokia, which bought French rival Alcatel-Lucent in 2016, said earlier this month that it could cut 597 jobs in France by end-2019 as part of a plan to save 1.2 billion euros ($1.4 billion) at group level.

Nokia Oyj (ADR) (NYSE:NOK)’s stock on Monday traded at beginning with a price of $6.25 and when day-trade ended the stock finally gained 0.81% to reach at $6.21. Analyst’s mean target price for NOK is $6.80 while analysts mean recommendation is 2.40. Stock value has moved between $4.03 – 6.68 in last one year.

Analyst’s ratings play a very important role in outlining a stock’s performance. Let us check out how analysts have ranked NOK based on current scenarios. Stock has got OUTPERFORM rating from 5 analyst(s) whereas last month 5 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 2 analyst(s) given BUY rating to the stock. Company fiscal year is ending in December and analysts’ consensus recommendation is Outperform for NOK and estimated EPS for next quarter is $ 0.06 .

Nokia Oyj (ADR) (NYSE:NOK) yearly performance is 13.53% and net profit margin is -1.80%. Annual EPS Growth of past 5 years is 17.80%. The current share price indicates that stock is -6.62% away from its one year high and is moving 53.71% ahead of its 52-week low.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)‘s stock on Monday traded at beginning with a price of $2.14 and when day-trade ended the stock finally moved up 5.69% to reach at $2.23. Analyst’s mean target price for IDRA is $5.75 while analysts mean recommendation is 1.70. Stock value has moved between $1.3 – 3.33 in last one year.

Analyst’s ratings play a very important role in outlining a stock’s performance. Let us check out how analysts have ranked IDRA based on current scenarios. Stock has got OUTPERFORM rating from 5 analyst(s) whereas last month 5 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 2 analyst(s) given BUY rating to the stock. Company fiscal year is ending in December and analysts’ consensus recommendation is Outperform for IDRA and estimated EPS for next quarter is $ -0.12 .

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) yearly performance is 3.24%. Annual EPS Growth of past 5 years is 21.70%. The current share price indicates that stock is -33.03% away from its one year high and is moving 71.54% ahead of its 52-week low.

On 18 September 2017, Oclaro, Inc. (NASDAQ:OCLR) stock price started the day at $9.16 and moved between $9.12 – 9.42 to finally close at $9.39. OCLR’s distance from 20 day simple moving average is 10.44% and distance from 50-Day simple moving average is 3.87%. In last 4 months performance of OCLR was -2.39% while its price to sale ratio is 2.55 and price to book ratio is 3.06.

Analysts expect Oclaro, Inc. (NASDAQ:OCLR) to report $ 0.20 EPS and has got OUTPERFORM rating from 6 of Thomson Reuters analysts and 0 analyst(s) given UNDERPERFORM rating. Analyst’s mean target price for OCLR is $12.64 while analysts mean recommendation is 1.80. Firm LT growth rate is estimated as 0.74 %.

Ally Financial Inc. (NYSE:ALLY)’s stock on Monday traded at beginning with a price of $22.66 and when day-trade ended the stock finally moved up 1.42% to reach at $22.90. Analyst’s mean target price for ALLY is $25.97 while analysts mean recommendation is 2.10. Stock value has moved between $16.72 – 23.61 in last one year.

Stock has got OUTPERFORM rating from 7 analyst(s) whereas last month 7 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 4 analyst(s) given BUY rating to the stock. Company fiscal year is ending in December and analysts’ consensus recommendation is Outperform for ALLY and estimated EPS for next quarter is $ 0.60 .

Ally Financial Inc. (NYSE:ALLY) yearly performance is 19.27% and net profit margin is 11.20%. Annual EPS Growth of past 5 years is 14.90%. The current share price indicates that stock is -3.05% away from its one year high and is moving 37.29% ahead of its 52-week low.

Leave a Reply

Your email address will not be published. Required fields are marked *